Cargando…
PEGylated arginine deiminase can modulate tumor immune microenvironment by affecting immune checkpoint expression, decreasing regulatory T cell accumulation and inducing tumor T cell infiltration
PEGylated arginine deiminase (ADI-PEG 20) is being investigated in clinical studies in arginine auxotrophic cancers and is well-tolerated. The anti-tumor properties of ADI-PEG 20 have been extensively investigated - ADI-PEG 20 inhibits the growth of auxotrophic cancers in vitro and in vivo - however...
Autores principales: | Brin, Elena, Wu, Katherine, Lu, Hsin-Tze, He, Yudou, Dai, Zhaoming, He, Wei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601705/ https://www.ncbi.nlm.nih.gov/pubmed/28938609 http://dx.doi.org/10.18632/oncotarget.19564 |
Ejemplares similares
-
Pegylated Arginine Deiminase Downregulates Colitis in Murine Models
por: Oz, Helieh S., et al.
Publicado: (2012) -
PEGylation increases antitumoral activity of arginine deiminase of Streptococcus pyogenes
por: Schwarz, Rico, et al.
Publicado: (2021) -
Checkpoint molecules on infiltrating immune cells in colorectal tumor microenvironment
por: Talaat, Iman M., et al.
Publicado: (2022) -
Pegylated arginine deiminase drives arginine turnover and systemic autophagy to dictate energy metabolism
por: Zhang, Yiming, et al.
Publicado: (2022) -
TRAIL stabilization and cancer cell sensitization to its pro-apoptotic activity achieved through genetic fusion with arginine deiminase
por: Brin, Elena, et al.
Publicado: (2018)